BXQ-350 nanovesicles have potent killing activity in vitro on more than 60 human
cancer cell lines. In vivo experiments in laboratory animals have shown significant inhibition and elimination
of tumors in all tested models including gliomas, human squamous cell carcinoma,
neuroblastoma, malignant peripheral nerve sheath tumor, head & neck cancer, acute
lymphoblastic leukemia (ALL) and pancreatic cancer. Recent data show that our nanovesicles
provide synergistic efficacy with current standard of care chemotherapies.
Mechanism-of-action studies indicate that BXQ-350 accelerates inherent cellular
digestive processes to kill tumor cells.
BXQ-350 has been shown to reduce tumor volume in both in vitro and in preclinical,
orthotopic mouse models of glioblastoma. High dose preclinical acute mouse studies
also indicate low toxicity.
Glioma Orthotopic Model
Aggressive brain tumor cells were implanted into 4 living mice.
Mice 1 and 2 were treated with BXQ-350 on days 5, 7, 9, 12, 14, 16;
Mice 3 and 4 received no treatment.
Tumor is visible in mice 1, 2 and 3.
No visible sign of tumor in mice 1 and 2; mice 3 and 4 show visible signs of tumor
No tumor is visible in mice 1 and 2; tumors continue to grow in mice 3 and 4
No visible sign of tumors in mice 1 and 2.
Tumors are aggressively growing in mice 3 and 4.
No tumor is visible in mice 1 and 2; mouse 4 has died and the tumor in mouse 3 continues
By day 72 mouse 3 has died; mice 1 and 2 continue to show no signs of tumor